Ipca Laboratories to merge with Krebs Biochemicals

Ipca Laboratories Ltd. announced its Board of Directors has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The merger is subject to regulatory approvals. The Appointed Date for the scheme is April 1, 2026. Ipca Laboratories had a total income of ₹7431 Crores for FY26, while Krebs Biochemicals had ₹26 Crores. The transaction is considered a related party transaction but will be conducted on an arm's length basis. Both companies operate in pharmaceutical manufacturing and marketing. The rationale includes operational synergies, cost optimization, business consolidation, and securing supply chains for key APIs and intermediates. Krebs Biochemicals possesses manufacturing capabilities for fermentation-based APIs that Ipca lacks. No cash consideration will be paid; instead, Ipca will issue 7 equity shares for every 200 shares of Krebs.